NDA 009458 · Impax Labs
Cortisone Acetate
Cortisone Acetate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 17, 2001 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Sep 17, 2001
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
171
38 Phase 3, 37 recruiting
FAERS reports
12,501
11,946 serious, 3,917 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Cortisone" as an intervention, any sponsor and status, largest first.
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00075725 · 3,154 participants · Start Dec 29, 2003 · Primary completion Dec 31, 2010
Drug: Cyclophosphamide; Cytarabine and 10 more · For: Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 234 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00408005 · 1,895 participants · Start Jan 30, 2007 · Primary completion Sep 30, 2017
Drug: Asparaginase; Cyclophosphamide and 12 more · For: T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 215 sites in all
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05675410 · 1,875 participants (planned) · Start May 11, 2023 · Primary completion Apr 28, 2031
Drug: Bleomycin Sulfate; Brentuximab Vedotin and 11 more · For: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 419 sites in all
- Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's DiseasePivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00025259 · 1,734 participants · Start Sep 2002 · Primary completion Aug 2012
Drug: Bleomycin Sulfate; Cisplatin and 8 more · For: Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma; Childhood Mixed Cellularity Classical Hodgkin Lymphoma; Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma and 5 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 175 sites in all
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Pivotal-lookingNot yet recruiting
Children's Oncology GroupResearch network
NCT07072585 · 1,708 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 1, 2035
Drug: Bortezomib; Calaspargase Pegol and 16 more · For: Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma and 2 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- systemic lupus erythematosus6,357
- pain6,279
- pemphigus6,238
- drug ineffective6,195
- alopecia6,123
- rheumatoid arthritis6,108
- abdominal discomfort6,037
- fatigue5,760
- glossodynia5,630
- swelling5,488
- hand deformity5,218
- wound5,067
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acute severe ulcerative colitis trials: the past, the present and the future.
Honap S, Jairath V, Sands BE, et al. · Gut 2024 · Systematic Review, Research Support, N.I.H., Extramural
- The Role of Hyaluronic Acid for Soft Tissue Indications: A Systematic Review and Meta-Analysis.
Khan M, Shanmugaraj A, Prada C, et al. · Sports Health 2023 · Meta-Analysis, Systematic Review
- Shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccination.
Bass JR, Poland GA · Vaccine 2022 · Systematic Review
- Corticosteroid rhythms in hypoparathyroid patients.
Astor MC, Løvås K, Methlie P, et al. · Eur J Endocrinol 2024 · Clinical Trial, Phase I
- Early childhood stress responses to psychosocial stressors: The state of the science.
Bates RA, Militello L, Barker E, et al. · Dev Psychobiol 2022 · Systematic Review
- Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia.
Abbas A, Schini M, Ainsworth G, et al. · J Clin Endocrinol Metab 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Impax Labs
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.